1. Home
  2. EYPT vs NETD Comparison

EYPT vs NETD Comparison

Compare EYPT & NETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • NETD
  • Stock Information
  • Founded
  • EYPT 1987
  • NETD 2023
  • Country
  • EYPT United States
  • NETD United States
  • Employees
  • EYPT N/A
  • NETD N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • NETD
  • Sector
  • EYPT Industrials
  • NETD
  • Exchange
  • EYPT Nasdaq
  • NETD Nasdaq
  • Market Cap
  • EYPT 390.0M
  • NETD 417.9M
  • IPO Year
  • EYPT 2005
  • NETD 2023
  • Fundamental
  • Price
  • EYPT $5.46
  • NETD $11.02
  • Analyst Decision
  • EYPT Strong Buy
  • NETD
  • Analyst Count
  • EYPT 7
  • NETD 0
  • Target Price
  • EYPT $24.00
  • NETD N/A
  • AVG Volume (30 Days)
  • EYPT 610.5K
  • NETD 199.6K
  • Earning Date
  • EYPT 05-07-2025
  • NETD 01-01-0001
  • Dividend Yield
  • EYPT N/A
  • NETD N/A
  • EPS Growth
  • EYPT N/A
  • NETD N/A
  • EPS
  • EYPT N/A
  • NETD 0.45
  • Revenue
  • EYPT $56,042,000.00
  • NETD N/A
  • Revenue This Year
  • EYPT N/A
  • NETD N/A
  • Revenue Next Year
  • EYPT N/A
  • NETD N/A
  • P/E Ratio
  • EYPT N/A
  • NETD $24.45
  • Revenue Growth
  • EYPT 12.04
  • NETD N/A
  • 52 Week Low
  • EYPT $3.91
  • NETD $10.50
  • 52 Week High
  • EYPT $21.26
  • NETD $11.10
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 43.45
  • NETD 57.82
  • Support Level
  • EYPT $5.75
  • NETD $10.97
  • Resistance Level
  • EYPT $6.29
  • NETD $11.03
  • Average True Range (ATR)
  • EYPT 0.47
  • NETD 0.03
  • MACD
  • EYPT -0.11
  • NETD -0.00
  • Stochastic Oscillator
  • EYPT 0.00
  • NETD 41.67

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About NETD Nabors Energy Transition Corp. II

Nabors Energy Transition Corp II is a blank check company.

Share on Social Networks: